Narcolepsy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight

DelveInsight’s Narcolepsy Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, July 3, 2024 /EINPresswire.com/ --
DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Narcolepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Narcolepsy Market Forecast

Some of the key facts of the Narcolepsy Market Report:
The Narcolepsy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
According to Slowik et al. (2022), narcolepsy type 1 has a prevalence of 14 per 100,000 people, while narcolepsy type 2 affects 65.4 per 100,000 people. The condition is most commonly diagnosed in late teens to early twenties and is 50% more prevalent among females in the US, based on data from 2008─2010.
According to Imanishi et al. (2022), a Japanese study using a health insurance claims database found that the overall annual prevalence of narcolepsy increased from 5.7 to 18.5 per 100,000 persons between 2010 and 2019. The largest increases were observed in patients aged 20–29 years and 10–19 years, with the highest prevalence in 2019 being 9.7–37.5 per 100,000 persons and 5.0–27.1 per 100,000 persons, respectively.
In the United States, narcolepsy is thought to afflict 1 in every 2,000 persons, according to the Narcolepsy Network Organisation. In contrast to paediatrics, adults are more often than children to suffer from narcolepsy, a sleep disease that is underdiagnosed
Slowik et al. (2022) estimate that the prevalence of narcolepsy type 1 is 14 per 100,000 people and type 2 is 65.4 per 100,000. According to research from 2008 to 2010, it is most prevalent in those who are in their late teens or early twenties, with a 50% greater female preponderance
Imanishi et al. (2022) in a Japanese study, which employed a health insurance claims database, found that in 2010 and 2019, the overall yearly prevalence climbed from 5.7 to 18.5/100,000 people
Key Narcolepsy Companies: NLS Pharmaceutics, Suven Life SciencesAlkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others
Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others
The Narcolepsy epidemiology based on gender analyzed that females are more affected with narcolepsy (type1) than males
The Narcolepsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Narcolepsy pipeline products will significantly revolutionize the Narcolepsy market dynamics.

Narcolepsy Overview
Narcolepsy is a chronic neurological disorder characterized by the brain's inability to regulate sleep-wake cycles normally. People with narcolepsy experience excessive daytime sleepiness and uncontrollable episodes of falling asleep during the day, regardless of the amount of nighttime sleep. These sudden sleep attacks can occur during any type of activity.

Get a Free sample for the Narcolepsy Market Report:
https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Narcolepsy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Narcolepsy Epidemiology Segmentation:
The Narcolepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Narcolepsy in the 7MM
Subtype-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM
Age-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM
Treated Cases of Narcolepsy in the 7MM

Download the report to understand which factors are driving Narcolepsy epidemiology trends @ Narcolepsy Epidemiology Forecast

Narcolepsy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched during the study period. The analysis covers Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Narcolepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Narcolepsy Therapies and Key Companies
QUILIENCE (mazindol ER): NLS Pharmaceutics
Samelisant (SUVN-G3031): Suven Life Sciences
NLS-2: NLS Pharmaceutics
ALKS 2680: Alkermes, Inc.
JZP258 (XYWAV): Jazz Pharmaceuticals
TS-091 5mg: Taisho Pharmaceutical
JZP-258: Jazz Pharma
SUVN-G3031: Suven Life Sciences Limited
JNJ-17216498: Alza Corporation, DE, USA
Modafinil: Cephalon
sodium oxybate: Orphan Medical
THN102 300/3: Theranexus
Mazindol: NLS Pharmaceutics
AXS-12 (Reboxetine): Axsome Therapeutics, Inc
TAK-861: Takeda
PF-03654746: Pfizer
FT218: Avadel
BTD-001: Balance Therapeutics

Narcolepsy Market Strengths
Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in narcolepsy.
The increasing prevalence of narcolepsy, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

Narcolepsy Market Opportunities
Identify potential therapeutic targets and strategies for improving quality of life, and restore functional levels of those who suffer from Narcolepsy
To understand the transition from acute to narcolepsy, how peripheral and central sensitization is manifested, and how they can be assessed

Scope of the Narcolepsy Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Narcolepsy Companies: NLS Pharmaceutics, Alkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others
Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others
Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies
Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Narcolepsy Unmet Needs, KOL’s views, Analyst’s views, Narcolepsy Market Access and Reimbursement

To know more about Narcolepsy companies working in the treatment market, visit @ Narcolepsy Clinical Trials and Therapeutic Assessment

Table of Contents
1. Narcolepsy Market Report Introduction
2. Executive Summary for Narcolepsy
3. SWOT analysis of Narcolepsy
4. Narcolepsy Patient Share (%) Overview at a Glance
5. Narcolepsy Market Overview at a Glance
6. Narcolepsy Disease Background and Overview
7. Narcolepsy Epidemiology and Patient Population
8. Country-Specific Patient Population of Narcolepsy
9. Narcolepsy Current Treatment and Medical Practices
10. Narcolepsy Unmet Needs
11. Narcolepsy Emerging Therapies
12. Narcolepsy Market Outlook
13. Country-Wise Narcolepsy Market Analysis (2020–2034)
14. Narcolepsy Market Access and Reimbursement of Therapies
15. Narcolepsy Market Drivers
16. Narcolepsy Market Barriers
17. Narcolepsy Appendix
18. Narcolepsy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here